{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-066482","form_type":"8-K","ticker":"IRIX","cik":"0001006045","company_name":"IRIDEX CORP","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.820434+00:00","generated_at":"2026-06-07T20:44:16.525816+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Iridex wins broader Medicare coverage for cyclophotocoagulation after LCD appeal","bullets":["Five Medicare Administrative Contractors corrected CPC coverage criteria; 'AND' changed to 'OR', broadening patient access.","Patient criteria now: failed trabeculectomy/tube shunt, minimal useful vision with elevated IOP, or need pain relief.","CEO David Bruce thanked MACs for quick action; appeal supported by Dr. Shan Lin, co-author of the 2001 AAO paper.","Iridex preparing subsequent appeal to further cover poor surgical candidates and emergency situations.","Change aligns LCDs with 2001 AAO paper; Iridex cites 22 years of technological advances and clinical studies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-066482","json":"https://secwatch.observer/filing/0000950170-23-066482.json","markdown":"https://secwatch.observer/filing/0000950170-23-066482.md","text":"https://secwatch.observer/filing/0000950170-23-066482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006045/000095017023066482/0000950170-23-066482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006045/000095017023066482/irix-20231127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:44:16.525816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}